Effect of risperidone on serum IL-6 levels in individuals with schizophrenia: a systematic review and meta-analysis

References

• Azizi, E., Zavaran Hosseini, A., & Soudi, S. (2019). Alteration of serum levels of cytokines in schizophrenic patients before and after treatment with risperidone. Iranian Journal of Allergy, Asthma, and Immunology, 18, 262–268. doi:10.18502/ijaai.v18i3.1119
   PubMed Web of Science ®Google Scholar
• Beeler, J. A., Faust, R. P., Turkson, S., Ye, H., & Zhuang, X. (2016). Low dopamine D2 receptor increases vulnerability to obesity via reduced physical activity, not increased appetitive motivation. Biological Psychiatry, 79(11), 887–897. doi:10.1016/j.biopsych.2015.07.009
   PubMed Web of Science ®Google Scholar
• Borovcanin, M. M., Jovanovic, I., & Radosavljevic, G. (2017). Interleukin-6 in schizophrenia-is there a therapeutic relevance? Frontiers in Psychiatry, 8, 221. doi:10.3389/fpsyt.2017.00221
   PubMed Web of Science ®Google Scholar
• Borovcanin, M. M., Minic Janicijevic, S., & Jovanovic, I. P. (2020). Type 17 immune response facilitates progression of inflammation and correlates with cognition in stable schizophrenia. Diagnostics, 10, 926. doi:10.3390/diagnostics10110926
   Web of Science ®Google Scholar
• Cerveri, G., Gesi, C., & Mencacci, C. (2019). Pharmacological treatment of negative symptoms in schizophrenia: Update and proposal of a clinical algorithm. Neuropsychiatric Disease and Treatment, 15, 1525–1535. doi:10.2147/ndt.S201726
   PubMed Web of Science ®Google Scholar
• Day, J. S., O'Neill, E., Cawley, C., Aretz, N. K., Kilroy, D., Gibney, S. M., Harkin, A., & Connor, T. J. (2014). Noradrenaline acting on astrocytic β2-adrenoceptors induces neurite outgrowth in primary cortical neurons. Neuropharmacology, 77, 234–248. doi:10.1016/j.neuropharm.2013.09.027
   PubMed Web of Science ®Google Scholar
• Dickerson, F., Severance, E., & Yolken, R. (2017). The microbiome, immunity, and schizophrenia and bipolar disorder. Brain, Behavior, and Immunity, 62, 46–52. doi:10.1016/j.bbi.2016.12.010
   PubMed Web of Science ®Google Scholar
• Dikeç, G., Arabaci, L. B., Uzunoglu, G. B., & Mizrak, S. D. (2018). Metabolic side effects in patients using atypical antipsychotic medications during hospitalization. Journal of Psychosocial Nursing and Mental Health Services, 56(4), 28–37. doi:10.3928/02793695-20180108-05
   PubMed Web of Science ®Google Scholar
• Dos Santos-Júnior, A., Henriques, T. B., de Mello, M. P., Della Torre, O. H., Paes, L. A., Ferreira-Neto, A. P., Sewaybricker, L. E., Fontana, T. S., Celeri, E. H. R. V., Guerra-Júnior, G., & Dalgalarrondo, P. (2016). Pharmacogenetics of risperidone and cardiovascular risk in children and adolescents. International Journal of Endocrinology, 2016, 1–10. doi:10.1155/2016/5872423
   Web of Science ®Google Scholar
• García, S., Martínez-Cengotitabengoa, M., López-Zurbano, S., Zorrilla, I., López, P., Vieta, E., & González-Pinto, A. (2016). Adherence to antipsychotic medication in bipolar disorder and schizophrenic patients: A systematic review. Journal of Clinical Psychopharmacology, 36(4), 355–371. doi:10.1097/jcp.0000000000000523
   PubMed Web of Science ®Google Scholar
• Girdler, S. J., Confino, J. E., & Woesner, M. E. (2019). Exercise as a treatment for schizophrenia: A review. Psychopharmacology Bulletin, 49(1), 56–69.
   PubMedGoogle Scholar
• Gumusoglu, S. B., Fine, R. S., Murray, S. J., Bittle, J. L., & Stevens, H. E. (2017). The role of IL-6 in neurodevelopment after prenatal stress. Brain, Behavior, and Immunity, 65, 274–283. doi:10.1016/j.bbi.2017.05.015
   PubMed Web of Science ®Google Scholar
• Jiang, N. M., Cowan, M., Moonah, S. N., & Petri, W. A. (2018). The impact of systemic inflammation on neurodevelopment. Trends in Molecular Medicine, 24(9), 794–804. doi:10.1016/j.molmed.2018.06.008
   PubMed Web of Science ®Google Scholar
• Khandaker, G. M., & Dantzer, R. (2016). Is there a role for immune-to-brain communication in schizophrenia? Psychopharmacology, 233(9), 1559–1573. doi:10.1007/s00213-015-3975-1
   PubMed Web of Science ®Google Scholar
• Kim, D. J., Kim, W., Yoon, S. J., Go, H. J., Choi, B. M., Jun, T. Y., & Kim, Y. K. (2001). Effect of risperidone on serum cytokines. The International Journal of Neuroscience, 111(1-2), 11–19. doi:10.3109/00207450108986549
   PubMed Web of Science ®Google Scholar
• Klemettilä, J.-P., Kampman, O., Seppälä, N., Viikki, M., Hämäläinen, M., Moilanen, E., & Leinonen, E. (2014). Cytokine and adipokine alterations in patients with schizophrenia treated with clozapine. Psychiatry Research, 218(3), 277–283. doi:10.1016/j.psychres.2014.04.049
   PubMed Web of Science ®Google Scholar
• Lian, J., De Santis, M., He, M., & Deng, C. (2015). Risperidone-induced weight gain and reduced locomotor activity in juvenile female rats: The role of histaminergic and NPY pathways. Pharmacological Research, 95-96, 20–26. doi:10.1016/j.phrs.2015.03.004
   PubMed Web of Science ®Google Scholar
• Lin, S., Fang, Y., Lin, Y., Mo, Z., Hong, X., Jian, Z., & Ji, C. (2021). Meta-analysis of the prognostic value of pretreatment serum ferritin in hepatobiliary and pancreas (HBP) cancers. BMJ Open, 11(5), e040801. doi:10.1136/bmjopen-2020-040801
   PubMed Web of Science ®Google Scholar
• Loh, K., Herzog, H., & Shi, Y. C. (2015). Regulation of energy homeostasis by the NPY system. Trends in Endocrinology and Metabolism: TEM, 26(3), 125–135. doi:10.1016/j.tem.2015.01.003
   PubMed Web of Science ®Google Scholar
• Maes, M., Bosmans, E., Ranjan, R., Vandoolaeghe, E., Meltzer, H. Y., De Ley, M., Berghmans, R., Stans, G., & Desnyder, R. (1996). Lower plasma CC16, a natural anti-inflammatory protein, and increased plasma interleukin-1 receptor antagonist in schizophrenia: Effects of antipsychotic drugs. Schizophrenia Research, 21(1), 39–50. doi:10.1016/0920-9964(96)00029-1
   PubMed Web of Science ®Google Scholar
• McNamara, R. K., Jandacek, R., Rider, T., & Tso, P. (2011). Chronic risperidone normalizes elevated pro-inflammatory cytokine and C-reactive protein production in omega-3 fatty acid deficient rats. European Journal of Pharmacology, 652(1-3), 152–156. doi:10.1016/j.ejphar.2010.11.010
   PubMed Web of Science ®Google Scholar
• Mirhafez, S. R., Pasdar, A., Avan, A., Esmaily, H., Moezzi, A., Mohebati, M., Meshkat, Z., Mehrad-Majd, H., Eslami, S., Rahimi, H. R., Ghazavi, H., Ferns, G. A., & Ghayour-Mobarhan, M. (2015). Cytokine and growth factor profiling in patients with the metabolic syndrome. British Journal of Nutrition, 113(12), 1911–1919. doi:10.1017/S0007114515001038
   PubMed Web of Science ®Google Scholar
• Momtazmanesh, S., Zare-Shahabadi, A., & Rezaei, N. (2019). Cytokine alterations in schizophrenia: An updated review. Frontiers in Psychiatry, 10, 892. doi:10.3389/fpsyt.2019.00892
   PubMed Web of Science ®Google Scholar
• Mondelli, V., Ciufolini, S., Belvederi Murri, M., Bonaccorso, S., Di Forti, M., Giordano, A., Marques, T. R., Zunszain, P. A., Morgan, C., Murray, R. M., Pariante, C. M., & Dazzan, P. (2015). Cortisol and inflammatory biomarkers predict poor treatment response in first episode psychosis. Schizophrenia Bulletin, 41(5), 1162–1170. doi:10.1093/schbul/sbv028
   PubMed Web of Science ®Google Scholar
• Müller, N., Myint, A.-M., Krause, D., Weidinger, E., & Schwarz, M. J. (2013). Anti-inflammatory treatment in schizophrenia. Progress in Neuro-Psychopharmacology & Biological Psychiatry, 42, 146–153. doi:10.1016/j.pnpbp.2012.11.008
   PubMed Web of Science ®Google Scholar
• Murphy, J., Pfeiffer, R. M., Lynn, B. C. D., Caballero, A. I., Browne, E. P., Punska, E. C., Yang, H. P., Falk, R. T., Anderton, D. L., Gierach, G. L., Arcaro, K. F., & Sherman, M. E. (2018). Pro-inflammatory cytokines and growth factors in human milk: An exploratory analysis of racial differences to inform breast cancer etiology. Breast Cancer Research and Treatment, 172(1), 209–219. doi:10.1007/s10549-018-4907-7
   PubMed Web of Science ®Google Scholar
• Na, K. S., Jung, H. Y., & Kim, Y. K. (2014). The role of pro-inflammatory cytokines in the neuroinflammation and neurogenesis of schizophrenia. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 48, 277–286. doi:10.1016/j.pnpbp.2012.10.022
   PubMed Web of Science ®Google Scholar
• Nahid, P., Jarlsberg, L. G., Kato-Maeda, M., Segal, M. R., Osmond, D. H., Gagneux, S., Dobos, K., Gold, M., Hopewell, P. C., & Lewinsohn, D. M. (2018). Interplay of strain and race/ethnicity in the innate immune response to M. tuberculosis. PLoS One, 13(5), e0195392. doi:10.1371/journal.pone.0195392
   PubMed Web of Science ®Google Scholar
• Noto, C., Ota, V. K., & Gouvea, E. S. (2014). Effects of risperidone on cytokine profile in drug-naïve first-episode psychosis. International Journal of Neuropsychopharmacology, 18, pyu042. doi:10.1093/ijnp/pyu042
   PubMed Web of Science ®Google Scholar
• Noto, C., Ota, V. K., Santoro, M. L., Gouvea, E. S., Silva, P. N., Spindola, L. M., Cordeiro, Q., Bressan, R. A., Gadelha, A., Brietzke, E., Belangero, S. I., & Maes, M. (2016). Depression, cytokine, and cytokine by treatment interactions modulate gene expression in antipsychotic naïve first episode psychosis. Molecular Neurobiology, 53(8), 5701–5709. doi:10.1007/s12035-015-9489-3
   PubMed Web of Science ®Google Scholar
• Noto, M. N., Maes, M., Nunes, S. O. V., Ota, V. K., Rossaneis, A. C., Verri, W. A., Cordeiro, Q., Belangero, S. I., Gadelha, A., Bressan, R. A., & Noto, C. (2019). Activation of the immune-inflammatory response system and the compensatory immune-regulatory system in antipsychotic naive first episode psychosis. European Neuropsychopharmacology, 29(3), 416–431. doi:10.1016/j.euroneuro.2018.12.008
   PubMed Web of Science ®Google Scholar
• Owen, M. J., Sawa, A., & Mortensen, P. B. (2016). Schizophrenia. The Lancet, 388(10039), 86–97. doi:10.1016/S0140-6736(15)01121-6
   PubMed Web of Science ®Google Scholar
• Rashid, R., Condon, L., Gluud, C., Jakobsen, J. C., Lindschou, J., & Lissau, I. (2020). Psychotherapy versus treatment as usual and other control interventions in children and adolescents with overweight and obesity: A protocol for systematic review with meta-analysis and Trial Sequential Analysis. BMJ Open, 10(11), e036058. doi:10.1136/bmjopen-2019-036058
   PubMed Web of Science ®Google Scholar
• Roh, E., & Choi, K. M. (2020). Health consequences of sarcopenic obesity: A narrative review. Frontiers in Endocrinology, 11, 332. doi:10.3389/fendo.2020.00332
   PubMed Web of Science ®Google Scholar
• Schultz, S. H., North, S. W., & Shields, C. G. (2007). Schizophrenia: A review. American Family Physician, 75(12), 1821–1829.
   PubMed Web of Science ®Google Scholar
• Song, X., Fan, X., Li, X., Zhang, W., Gao, J., Zhao, J., Harrington, A., Ziedonis, D., & Lv, L. (2014). Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. Psychopharmacology, 231(2), 319–325. doi:10.1007/s00213-013-3382-4
   PubMed Web of Science ®Google Scholar
• Srinivas, L., Vellichirammal, N. N., Alex, A. M., Nair, C., Nair, I. V., & Banerjee, M. (2016). Pro-inflammatory cytokines and their epistatic interactions in genetic susceptibility to schizophrenia. Journal of Neuroinflammation, 13(1), 105. doi:10.1186/s12974-016-0569-8
   PubMedGoogle Scholar
• Stang, A. (2010). Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. European Journal of Epidemiology, 25(9), 603–605. doi:10.1007/s10654-010-9491-z
   PubMed Web of Science ®Google Scholar
• Tsolakis, A. V., Ragkousi, A., Vujasinovic, M., Kaltsas, G., & Daskalakis, K. (2019). Gastric neuroendocrine neoplasms type 1: A systematic review and meta-analysis. World Journal of Gastroenterology, 25(35), 5376–5387. doi:10.3748/wjg.v25.i35.5376
   PubMed Web of Science ®Google Scholar
• Vanwong, N., Ngamsamut, N., Nuntamool, N., Hongkaew, Y., Sukprasong, R., Puangpetch, A., Limsila, P., & Sukasem, C. (2020). Risperidone-induced obesity in children and adolescents with autism spectrum disorder: Genetic and clinical risk factors. Frontiers in Pharmacology, 11, 565074. doi:10.3389/fphar.2020.565074
   PubMed Web of Science ®Google Scholar
• Ventriglio, A., Baldessarini, R. J., Vitrani, G., Bonfitto, I., Cecere, A. C., Rinaldi, A., Petito, A., & Bellomo, A. (2018). Metabolic syndrome in psychotic disorder patients treated with oral and long-acting injected antipsychotics. Frontiers in Psychiatry, 9, 744. doi:10.3389/fpsyt.2018.00744
   PubMed Web of Science ®Google Scholar
• Venugopal, D., Shivakumar, V., Subbanna, M., Kalmady, S. V., Amaresha, A. C., Agarwal, S. M., Narayanaswamy, J. C., Banerjee, M., Debnath, M., & Venkatasubramanian, G. (2018). Impact of antipsychotic treatment on methylation status of interleukin-6 [IL-6] gene in schizophrenia. Journal of Psychiatric Research, 104, 88–95. doi:10.1016/j.jpsychires.2018.07.002
   PubMed Web of Science ®Google Scholar
• Vidal, P. M., & Pacheco, R. (2020). The cross-talk between the dopaminergic and the immune system involved in schizophrenia. Frontiers in Pharmacology, 11, 394. doi:10.3389/fphar.2020.00394
   PubMed Web of Science ®Google Scholar
• Wan, X. Q., Zeng, F., Huang, X. F., Yang, H. Q., Wang, L., Shi, Y. C., Zhang, Z. H., & Lin, S. (2020). Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway. CNS Neuroscience and Therapeutics, 26(5), 558–566. doi:10.1111/cns.13281
   PubMed Web of Science ®Google Scholar
• Wiciński, M., Gębalski, J., & Gołębiewski, J. (2020). Probiotics for the treatment of overweight and obesity in humans-A review of. clinical trials. Microorganisms, 8, 1148. doi:10.3390/microorganisms8081148
   Google Scholar
• Yolken, R. H., & Torrey, E. F. (1995). Viruses, schizophrenia, and bipolar disorder. Clinical Microbiology Reviews, 8(1), 131–145. doi:10.1128/cmr.8.1.131-145.1995
   PubMed Web of Science ®Google Scholar
• Zanger, U. M., & Schwab, M. (2013). Cytochrome P450 enzymes in drug metabolism: Regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology and Therapeutics, 138(1), 103–141. doi:10.1016/j.pharmthera.2012.12.007
   PubMed Web of Science ®Google Scholar
• Zhang, X. Y., Zhou, D. F., Qi, L. Y., Chen, S., Cao, L. Y., Chen, D. C., Xiu, M. H., Wang, F., Wu, G. Y., Lu, L., Kosten, T. A., & Kosten, T. R. (2009). Superoxide dismutase and cytokines in chronic patients with schizophrenia: Association with psychopathology and response to antipsychotics. Psychopharmacology, 204(1), 177–184. doi:10.1007/s00213-008-1447-6
   PubMed Web of Science ®Google Scholar
• Zhou, Y., Ingelman-Sundberg, M., & Lauschke, V. M. (2017). Worldwide distribution of cytochrome P450 alleles: A meta-analysis of population-scale sequencing projects. Clinical Pharmacology and Therapeutics, 102(4), 688–700. doi:10.1002/cpt.690
   PubMed Web of Science ®Google Scholar